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The  malaria  sporozoite  injected  into  a  host  by  the bite  of the  mosquito  vector 
initiates the parasite cycle that culminates in clinical disease. This sporozoite stage is 
highly antigenic,  and  immunization  with  irradiated  sporozoites  has  prevented  the 
development  of malaria  in  rodent  and  simian  hosts  as  well  as  in  several  human 
volunteers  (1).  Antisporozoite  antibodies  detectable  in  the sera  of the  immunized 
primate hosts appear to be associated with immune resistance. 
Recently,  hybridoma-derived  monoclonal antibodies  directed  against  sporozoites 
of rodent and simian malaria were found to be protective,  i.e., to abolish sporozoite 
infectivity both in vivo (2) and in vitro (3). 1 These antibodies react with circumspo- 
rozoite  (CS) 2  proteins;  that  is,  stage-  and  species-specific  polypeptides  that  are 
uniformly distributed over the entire surface of the parasite and that are shed when 
cross-linked by antibodies (2, 4). 1 
The  hybridoma  technique was  therefore  used to develop  monoclonal  antibodies 
against sporozoites of P falciparum and P. vivax in an attempt to identify the protective 
antigens of the human pathogens for their application in a vaccine. 
Materials and Methods 
Mice.  BALB/c mice were immunized using viable and frozen sporozoites of P.falciparum  or 
P.  vivax. The  P. falciparum  spomzoites  were  of West  African  origin  and  were  obtained  by 
membrane feeding Anopheles gambiae mosquitoes on blood obtained  from patients  carrying P. 
falciparum  gametoeytes.  P.  vivax  sporozoites  for  immunization  were  obtained  from Anopheles 
* Supported in part by AID grant TAC 1199; National Institutes of Health Training grant GM 07552; 
National Institutes of Health Grant 5 ROI AI 17429; UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Medicine; Yerkes Center base grant RR 00165 NIH; and a grant from 
the Rockefeller Foundation. 
1 Cochrane, A. H., F.  Santoro, V.  Nussenzweig,  R. W. Gwadz, and  R. S. Nussenzweig.  Monoclonal 
antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Manuscript submitted for 
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mosquitoes that had fed on Aotus monkeys infected with P. vivax of Southeast Asian origin (Indo 
I/CDC, Ong/CDC, and New Guinea/CDC, strains). 
The P. falciparum and P. vivax sporozoite-immunized mice received seven and ten intravenous 
injections,  respectively, totalling  ~5.0  ×  10  n sporozoites.  Spleens  were  removed  from  the 
immunized mice 3  d  after the last booster, at  a  time when  antisporozoite antibodies were 
detectable in their sera. 
Hybridomas.  Hybridomas were produced by fusing the spleen cells from the hyperimmunized 
mice with NS1  myeloma cells (5) using minor modifications of the technique of Kohler and 
Milstein (6). 
The presence of antisporozoite antibodies in the hybridoma culture supernatant was detected 
by indirect immunofluorescence (IFA) using glutaraldehyde-fixed  sporozoites of the appropriate 
species as antigen. Cells in IFA-positive wells were expanded, cloned by limiting dilution, and 
injected into pristane-primed CD2F1 mice to obtain larger quantities ofascites fluid and serum. 
Monoclonal Antibodies.  The  antibody class of the  hybridoma was  determined  by  double 
diffusion in agar using the concentrated culture supernatants reacted against antisera specific 
for immunoglobulin class heavy and light chains (Litton Bionetics, Kensington, MD). Partial 
purification of the monoclonal antibody was carried out by precipitating pooled ascites fluid 
from the hybridoma-bearing mice in 50% ammonium sulfate. The precipitate was dissolved in 
phosphate-buffered saline and  subjected to  chromatography in  a  Sephadex G-200 column 
(Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N  J). The antibody was eluted 
in the second optical density peak. Monovalent fragments were obtained by papain digestion 
(7). 
The specificity of the monoclonal antibodies was determined using the circumsporozoite 
precipitation reaction (CSP) (8) and/or indirect immunofluorescence (9). The CSP reaction is 
a  precipitate that  forms at the posterior end of viable sporozoites after incubation with the 
appropriate antisporozoite antibody. The IFA assay was carried out using multiple well slides 
containing  sporozoites fixed  in  0.1%  glutaraldehyde.  After  reaction  with  the  monoclonal 
antibody, the washed slides were stained with fluorescein isothiocyanate-conjugated goat anti- 
mouse F(ab')2 IgG (N. L. Cappel Laboratories, Inc., Cochranville, PA) using Evans Blue as a 
counterstain. 
Parasite Species and Strains.  The monoclonal antibodies were tested against sporozoites of 
human (P. falciparum, P  vivax), simian (P. knowlesi, P. cynoraolgO, and rodent (P. berghe  0  malaria 
and also against P. falciparura-infected  erythrocytes obtained from in vitro culture. P. falciparum 
sporozoites of West African (Gambia) and Southeast Asian (Thailand) origin were derived from 
human  gametocyte carriers.  Strains  of P.  vivax sporozoites for  testing were  obtained  from 
mosquitoes fed on  human  or monkey hosts infected with  Southeast  Asian  (Thailand,  New 
Guinea/CDC, Ong/CDC, Indo I/CDC) or Central American (Sal I/CDC) vivax strains. 
Sporozoite Neutralization Assay.  The  biological activity  of the  monoclonal  antibody  was 
determined  by  the  sporozoite  neutralization  assay  (10)  in  which  viable sporozoites were 
incubated for 45 min at room temperature with Fab fragments or intact monoclonal antispo- 
rozoite antibodies. In most of the experiments, Fab fragments rather than the native molecules 
were used to assay for effects of the primary antigen-antibody reaction on parasite infectivity. 
As controls, an  equal  number of sporozoites were incubated  in tissue culture Medium  199 
(Gibco, Grand Island Biological Co., Grand Island, NY) or with Fab of a monoclonal antibody 
(3Dll)  directed  against  Pb44,  the  protective  antigen  of P.  berghei sporozoites  (2).  After 
incubation, the sporozoites were injected intravenously into splenectomized chimpanzees. Blood 
smears were obtained at 2-d intervals and examined after Giemsa staining to determine the 
presence of a  patent malaria infection. Chemotherapy was initiated as soon as patency was 
confirmed. 
The  chimpanzees  were  maintained  in  the  Laboratory  for  Experimental  Medicine  and 
Surgery in Primates, New York University Medical Center, New York, or Yerkes Regional 
Primate Research Center, Emory University, Atlanta, GA. 
Two neutralization experiments were performed with P. falciparum, one involving four, and 
the other, five chimpanzees. In both instances, the salivary glands of mosquitoes that fed on 
blood from patients from Thailand were the source of sporozoites. Before injection into the 
splenectomized chimpanzees, the sporozoites were incubated with 0.4-0.5 ml (2.5  mg) of the 22  CIRCUMSPOROZOITE PROTEINS OF HUMAN MALARIA PARASITES 
specific or control monoclonals. In the first  experiment,  each chimpanzee received  2  ×  104 
sporozoites, and in the second, 1 ×  104 sporozoites. 
Two neutralization experiments with P. vivax were carried out in the same way with P. vivax 
from Thailand, using 2 ×  104 sporozoites per animal. Experimental animals received sporozoites 
incubated  with  0.4 ml  (2.2  mg)  of Fab  fragments or intact  monoelonal antibody directed 
against P.  vivax sporozoites. Control chimpanzees received sporozoites incubated with either 
Fab of a nonrelated monoclonal antibody (2 mg) or tissue culture medium. 
Immunoprecipitation of Sporozoite Antigens.  Viable sporozoites of either P. falciparum (Thailand 
origin) or P. vivax (Ong/CDC strain) were incubated for 2-4 h in methionine-free RPMI 1640 
to which was added 200 #Ci of [mS]methionine (New England Nuclear, Boston, MA) using the 
method of Yoshida et al.  (11). Protease inhibitors were added to the labeled sporozoites before 
extraction with  1% Nonidet P-40 (N-P40; Particle Data Laboratories, Ltd., Cedarhurst,  IL). 
The labeled sporozoite extracts were reacted overnight at 4°C with antibodies. 
The antigen/antibody complexes were bound to Staphylococcus aureus, Cowan I strain  (Pan- 
sorbin, Calbiochem-Behring, La Jolla, CA) (12), washed, and then eluted with sample buffer 
containing 2%  sodium  dodecyl sulfate  (SDS),  20% /3-mercaptoethanol,  and  6  M  urea.  The 
eluates were subjected to SDS-potyaerylamide gel electrophoresis (SDS-PAGE) (13). The dried 
gels were stained with Coomassie Blue,  treated  with  Enhance  (New England Nuclear), and 
exposed  to film  (Kodak X-Omat  AR,  Eastman  Kodak Co.,  Rochester,  NY)  for a  variable 
period of time at -70°C before the fluorographs were developed. 
As a source of antibodies to sporozoites, we used the monoclonal anti-P,  vivax and anti-P. 
falciparum and, in addition, the sera of human volunteers who were protected against challenge 
with either sporozoites of P. fatciparum  (14) or P.  viva× (15)  after immunization by multiple 
exposures  to  the  bites  of irradiated  malaria-infected  mosquitoes.  The  volunteer  protected 
against P. falciparum was immunized with and resistant to challenge by P. falciparum sporozoites 
of the Thau strain  (Burma origin).  He was also protected against challenge with sporozoites 
from  other  P. falciparum  strains  from  Malaya,  Panama,  and  the  Philippines,  but  was  not 
protected  against  P.  vivax sporozoites  (16). The  volunteer who successfully  resisted  P.  vivax 
sporozoite challenge had been immunized by exposure to the bites of irradiated  mosquitoes 
infected with a Central American vivax strain (Cue., El Salvador) and the Chesson strain from 
New Guinea-South Pacific. 
The sera  of the immunized  volunteers were kindly provided by Dr. Vincent  McCarthy, 
University of Maryland Medical  School. Additional immunoprecipitations were carried out 
using a monoclonal antibody directed against sporozoites of rodent malaria P. berghei (3D11) 
(3), two monoelonal antibodies directed against P. knowlesi sporozoites (2G3 and  8A8),  1 and 
normal serum from rodents and humans. 
Results 
Characterization  of the  Monoclonal Antibodies  to P.  vivax and P. falciparum.  The single 
anti-P, falciparurn  sporozoite monoclonal antibody that  we obtained  was  designated 
3D6 and was identified as an IgG1 immunoglobulin with a x light chain. The anti-P. 
vivax  sporozoite  monoclonal  antibody,  designated  2F2,  was  identified  as  an  IgG2b 
immunoglobulin and also had a ~ light chain. 
Positive  IFA reactions  were obtained  with  concentrations  as low as 0.3/~g/ml  of 
purified 3D6 or 0.1 #g/ml of 2F2 when tested against glutaraldehyde-fixed sporozoites 
of the homologous species. As shown by the pattern of fluorescence, the monoclonals 
reacted with the entire surface membrane of the parasites. Neither monoclonal reacted 
in the IFA assay with  sporozoites of simian  (P. knowlesi,  P.  cynomolgi)  or rodent  (P. 
berghei)  malaria, nor with the P. falciparum blood stage parasites. 
Both  monoclonals  gave  CSP  reactions  at  high  dilutions  of serum  (1:256)  when 
incubated  with  viable  sporozoites  of the  homologous but  not  heterologous  species. 
The specific antigen detected on the surface of P. falciparum and P. vivax sporozoites by 
the respective monoclonal antibodies was shared by sporozoites of the same plasmodial NARDIN ET  AL.  23 
species, regardless of the geographic origin of the parasites. Thus, the anti-P, falciparum 
monoclonal that was derived from spleen cells of a mouse immunized with sporozoites 
of West  African  origin  (Gambia)  gave  a  high  CSP  titer  when  incubated  with  P. 
falciparum sporozoites obtained from Thailand. Similarly, the anti-P, vivax monoclonal 
raised using spleen cells from  mice immunized with  sporozoites of Southeast  Asian 
strains  gave  CSP  reactions  with  P.  vivax  sporozoites  from  Central  America  (El 
Salvador) as well as from Thailand (Table I). 
To characterize the CS antigens involved in these reactions, extracts of sporozoites 
biosynthetically  labeled  with  [aSS]methionine  were  immunoprecipitated  with  the 
monoclonals (Table I). In the case of [aSS]methionine-labeled P. falciparum  (Thailand) 
sporozoites (Fig. 1), two specific bands of-67,000  and 58,000 mol wt (Pf67 and Pf58) 
were precipitated by both the monoclonal antibody against P. falciparum sporozoites 
(3D6)  (track b) and by the serum of the human  volunteer immunized and protected 
against  P. falciparum  sporozoite challenge  (track  c).  The  Pf67  band  appeared  as  a 
doublet  and  consists of two  different  polypeptides. In  some  experiments  Pf58  was 
poorly labeled (Fig. 2). It appears that the amount of label incorporated into the low 
TABLE  I 
Antibodies  Results of CSP and/or IFA 
reactions with sporozoites of 
Specific 
immunoprecipitation from 
[aSS]met  hionine-labeled 
sporozoites of 
P falciparum  P. vivax  P falciparum  P. vivax 
Origin  Immunogen  Cen-  South- 
sporozoites of  West  South-  tral  Southeast  Southeast 
Africa  east  east  Asia  Amer-  Asia  Asia  Asia  ica 
Hybridoma  P. falciparum  +  +  -  -  Pf 67  None 
3D6  (West Africa)  Pf 58 
Hybridoma  P. vivax  -  -  +  +  None  Pv 51 
2F2  (S.E. Asia)  Pv 45 
Hybridoma  P. knowlesi  +  +  -  -  Pf 67*  ND:~ 
2G3  (H. strain) 
Human serum  P. faldparum  +  +  -  -  Pf 67 
(S.E. Asia)  ef 58 
(Pf 80)§  (Pv 78) 
Human serum  P. vioax  -  -  +  +  Pv 51 
(Central America  Pv 45 
and S. E. Asia)  (Pf 80)  (Pv 78) 
* In this experiment, the immunoprecipitation of the P falciparum extract by 31)6 and 2G3 yielded  only one 
specific band, that is, Pf67 (see Fig. 2 and text). 
1: Not done. 
§ Antigens in parenthesis are not species specific: Pf80 was immunoprecipitated by human anti-P,  vivax 
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Fro.  1.  Analysis  of SDS-PAGE  of [~OS]methionine-labeled P. fakiparum  (Thailand)  sporozoite 
extract,  immunoprecipitated with purified monoclonal anti-P, falciparum sporozoite antibody (3D6) 
(track  b) or with serum obtained from a  human volunteer immunized and protected  against P. 
falciparum sporozoites  (track c). The radiolabeled P. falciparum sporozoite  extract  was also reacted 
with serum of a human volunteer immunized against P. vivax sporozoites (track d) and a purified 
monoclonal antibody directed against P. vivax sporozoites (2F2) (track e). The results of immuno- 
precipitation with normal human serum are shown in track a. 
Fro.  2.  [SSS]methionine-labeled P. faMparum (Thailand) sporozoites analyzed by SDS-PAGE after 
immunoprecipitation with purified monoclonal anti-P, falciparum sporozoite  antibody (track  c), 
antiserum obtained from a human volunteer immunized against P. falciparum sporozoites (track b), 
a  cross-reacting  monoclonal anti-P, knowlesi sporozoite  antibody (2G3) (track  d),  or a  non-cross- 
reacting monoclonal anti-P, knowlesi sporozoite antibody (8A8) (track e). A normal human serum 
control is shown in track a. Track f shows [3nS]methionine P. falciparum sporozoites immunoprecipi- 
tated with antiserum obtained from a human volunteer immunized against P. vivax  sporozoites. 
molecular weight protein depends on the viability of the parasites, but this could not 
be studied further because of the scarcity of P. falciparum sporozoites. 
Pf67  is species specific because it is not recognized by monoclonals to P. vivax (Fig. 
1,  track  e)  or  P.  berghei  (not  shown  in  this  figure)  or  by  the  serum  of the  human 
volunteer immunized  with P.  vivax  (Fig.  1,  track  d;  Fig.  2,  track  f).  An  unexpected 
finding was  that  one  of the  monoclonals  raised  against  CS  proteins  of P.  knowlesi 
sporozoites  (2G3)  that  cross-reacts with P. cynomolgi, 1 also bound to the membrane  of 
P. falciparum, as determined by CSP and IFA assays. As shown in Fig. 2  (track d), 2G3 
also immunoprecipitated Pf67. Another monoclonal antibody to the CS proteins of P. 
knowlesi (8A8) did not cross-react with the P. falciparum sporozoites by IFA  1 and failed 
to immunoprecipitate Pf67  from the radiolabeled sporozoite extract  (Fig. 2, track e). 
In addition to the Pf67 band, a  polypeptide of 80,000 mol wt  (PfS0) was immunopre- NARDIN ET AL.  25 
cipitated  by  the  sera  of both  the  P. falciparum-  and  the  P.  vivax-immunized  human 
volunteers (Fig. 2, compare track b and track f; Fig.  1, track c and track d, very faint). 
The CS antigens of P. vivax sporozoites were also characterized by biosynthetically 
labeling the parasites with [~S]methionine and immunoprecipitating the extract with 
monoclonal  antibody  2F2  (Fig.  3,  track  d).  The  fluorograph  of the  SDS-PAGE 
revealed two major specific bands of apparent  45,000  (Pv45)  and 51,000  (Pv51)  mol 
wt. The Pv51  band is very broad and it may contain more than one polypeptide.  A 
very similar pattern was obtained when the radiolabeled  extract was immunoprecip- 
itated with serum obtained from the human volunteer immunized and resistant  to P. 
vivax sporozoite challenge  (Fig. 3, track a). 
Pv45  and  Pv51  are  species  specific  and  were  not  precipitated  by  a  monoclonal 
antibody  directed  against  P.  berghei (3D11)  (Fig.  3,  track  e)  or  by the  monoclonal 
antibody directed against P. falciparum sporozoites (3D6)  (not shown in Fig. 3), or by 
the serum of the volunteer immunized and protected against P. falciparum sporozoites 
(Fig.  3,  track  b).  As  was  the  ease  with  P. falciparum  sporozoites,  an  additional 
polypeptide  (Pv78)that  is not species  specific can  be  precipitated  from the P. vivax 
extract  by both  the serum  of the P.  vivax- and  the P. falciparum-immunized  human 
volunteer. 
Neutralization of Sporozoites of P. falciparum and P. vivax by Monoclonal Antibodies.  The 
monoclonal 3D6 was tested  for its ability to neutralize  the infectivity of P. falciparum 
sporozoites as described in the Materials  and Methods section. Two separate experi- 
ments were carried out in chimpanzees  (Table II). 
In experiment  I, the two control chimpanzees  that  received  2  ×  104 P. falciparum 
FIG.  3.  Analysis  by SDS-PAGE of proteins immunoprecipitated  from a  [~S]methionine-labeled 
extract of P. vivax  sporozoites (Ong/CDC strain) by antiserum obtained  from a human volunteer 
immunized against P. vivax  sporozoites (track a), a human volunteer immunized against P.falciparum 
sporozoites (track b), serum of CD2F1 mice  bearing a hybridoma against P vivax  sporozoites (2F2) 
(track d), or serum of CD2F1 mice bearing a hybridoma against sporozoites of rodent malaria P. 
berghei (3DI1)  (track e).  Track  c  contains  radiolabeled  molecular  weight markers. The heavy 
background observed in track d appears to be the result of nonspecific trapping  of radiolabeled 
material in the monoclonal precipitate. The monoclonal anti-P, vivax  antibody  (2F2) precipitated 
~7.7% of the radiolabeled vivax extract as compared to only 1.3% of the counts being precipitated 
by 3DI1.  Subsequent  gels have shown that  this nonspecific background  can  be eliminated  by 
preabsorption of the labeled sporozoite extract with Staph A before immunoprecipitation with the 
monoclonal antibody. 26  CIRCUMSPOROZOITE PROTEINS OF HUMAN MALARIA PARASITES 
TABLE  II 
Sporozoite Neutralization Experiments Using Monoclonat Antisporozoite Antibodies 
Chimpanzees injected  Experimentals,  first day of  Controls,  first day of 
Experiment  with sporozoites of  pateney  patency 
I*  P. falciparum  21, not patent¢  12, 14 
II§  P. falciparum  21, 25  14, 14, 14 
III[[  P. vivax  36, not patent¶  17, 21 
IV**  P. vivax  21, 28, 33  19, 19, 24 
* Each animal received 2 ×  104 P. falczparurn (Thailand) sporozoites. The two experimental chimpanzees 
received parasites incubated with Fab of 3D6 (2.5 mg). The two controls were injected with sporoznites 
incubated with Fab of 3D11 (2.5 mg) or tissue culture medium, respectively. 
Experiment terminated on day 61. 
§ Same experimental conditions as in experiment I, except that each animal received I ×  104 sporozoites. 
Controls received parasites incubated in tissue culture medium. 
II All chimpanzees were injected with  2 ×  104 P.  vivax (Thailand)  sporozoites. Experimental  animals 
received sporozoites incubated in Fab of 2F2 (2.2 mg). Control was tissue culture medium. 
¶ Experiment terminated on day 79. 
** Conditions are the same as in experiment III, except that the third experimental chimpanzee received 
sporozoites incubated with intact 2F2. The first and the third control chimpanzees received sporozoites 
incubated with Fab of 3D11 (2 rag), while the second received parasites in tissue culture medium. 
sporozoites  incubated  either  in  Fab  fragments  of a  monoclonal  antibody  directed 
against  P.  berghei sporozoites  (3Dll)  or in Medium  199 became patent  12 and  14 d 
post-inoculation, respectively. Of the two chimpanzees injected with the P. falciparum 
sporozoites incubated with  Fab  fragments of the monoclonal anti-P, falciparum  anti- 
body (3D6), one developed a patent infection 21 d post-injection. The second recipient 
of 3D6 remained negative until the experiment was terminated 61 d after the injection 
of parasites. 
In  the  second  experiment,  the  three  control  chimpanzees  that  received  1  ×  104 
sporozoites incubated  in tissue culture medium, showed patent  infections  14 d  post- 
injection.  The two experimental  animals  injected  with  the sporozoites  incubated  in 
Fab fragments of monoclonal 3D6 showed delayed prepatent  periods of 21  and 25 d. 
Two sporozoite-neutralizing  experiments,  involving a  total  of 10  splenectomized 
chimpanzees,  were  carried  out  to  test  the  ability  of the  monoclonal  anti-P,  vivax 
antibody (2F2)  to decrease sporozoite infectivity. In the first experiment,  two control 
chimpanzees,  each  injected  with  2  ×  104  viable  P.  vivax  (Thailand)  sporozoites 
incubated in Medium  199, developed vivax malaria  17 and 21 d  post-inoculation. Of 
the two chimpanzees that received sporozoites incubated with the Fab fragments of 
the monoclonal anti-P,  vivax  antibody  (2F2), one had a  delayed prepatent  period of 
36 d, while the other remained negative. 
The second vivax experiment was carried out using six splenectomized chimpanzees, 
each injected with 2 ×  104 P. vivax (Thailand)  sporozoites. Two controls that received 
sporozoites incubated with Fab of3D11 became infected 19 and 24 d post-inoculation. 
The  third  control,  injected  with  P.  vivax  sporozoites  incubated  with  tissue  culture 
medium, was patent  19 d  after injection.  Two experimental  chimpanzees inoculated 
with sporozoites incubated with Fab of 2F2 had detectable parasitemia  21  and 28 d 
post-inoculation.  The  third  experimental  animal,  which  received  sporozoites  incu- 
bated with intact molecules of 2F2, developed vivax malaria 33 d  after injection. NARDIN ET AL.  27 
Discussion 
One of the main findings of the present paper is that the interaction of monoclonal 
antibodies 3D6 and 2F2 with CS proteins of P. falciparum  and P. vivax diminishes the 
infectivity of the parasites. 
In  two  separate  experiments  (Table  II)  involving a  total  of nine  chimpanzees 
injected with  1-2  X  104  P. faldparum  sporozoites,  the  five control  animals became 
patent between  12 and  14 d  after the injection, whereas in the experimental group, 
one animal failed to develop patency, and in the three others the prepatent periods 
were 21, 21, and 25 d. Very similar results were obtained in 10 chimpanzees injected 
with 2 ×  104 P. vivax sporozoites. The four controls became patent between 17 and 24 
d, whereas in the experimental group, one animal did not become infected and the 
other four had prepatent periods of 21, 28, 33, and 36 d. 
Although complete neutralization was not achieved, these results are encouraging 
for several reasons. In the first place, 3D6 and 2F2 are the first and only monoclonals 
that we have raised against the CS proteins of P. falciparum  and P. vivax. The delay in 
patency observed in the experimental animals suggests that a large proportion of the 
injected  sporozoites  might  have  been  neutralized  by  the  antibodies  because  in 
experimental  models  of malaria  the  dose-response  curve  relating  the  number  of 
injected sporozoites  to  the  prepatent  period  is  very flat.  For example,  in  several 
experiments, a  variation of <1  d in the prepatent period occurred in groups of mice 
injected with 10  s or 5 X  10  a P. berghei sporozoites (17). Also, no significant variation 
in prepatent period was observed in monkeys injected with between  10  a or 5 ×  104 
sporozoites of P. cynomolgi (18). 
Because  monovalent  fragments  of monoclonal  antibodies  to  CS  proteins  have 
neutralizing activity, it is very likely that the effect observed is a direct consequence 
of the primary antigen-antibody reaction rather  than of secondary effects in vivo, 
which could lead to the elimination of parasites such as complement-mediated lysis 
or  phagocytosis.  In  rodent  and  monkey malaria  models,  Fab  fragments of CSP- 
inducing monoclonals also neutralize their infectivity, suggesting that the correspond- 
ing CS proteins play a role in parasite infectivity. In fact, Fab fragments to Pb44, the 
P. berghei CS antigen, inhibit adhesion and intracellular development of the parasite 
in target cells in vitro (19). 
The species specificity but not strain specificity of the antibodies to the CS proteins 
of P.  vivax  and  P. falciparum  (Table  I)  is  consistent  with  the  earlier  data  on  the 
characteristics of the humoral response and protective immunity to sporozoites (1). 
An additional important observation was that the P. falciparum  of Southeast Asian 
origin used to inject the chimpanzees was neutralized by monoclonal antibodies raised 
against a West African isolate of the parasite. 
Both the monoclonals 3D6 (anti-P. falciparum)  and 2F2 (anti-P. vivax) immunopre- 
cipitated  two  antigens  of different  molecular  weight  (Pf67  and  Pf58;  and  Pv51 
and  Pv45)  from  extracts  of the  homologous parasites  metabolically labeled  with 
[aSS]methionine.  Pf67 and Pf58 are structurally related because their tryptic peptide 
maps obtained by high performance liquid chromatography on C 18 columns are very 
similar,  if not  identical  (F.  Santoro,  A.  Cochrane,  E.  H.  Nardin,  R.  Gwadz,  R. 
Nussenzweig,  V.  Nussenzweig,  and  A.  Ferreira,  manuscript  in  preparation).  The 
relationship between each pair of polypeptides and the corresponding membrane- 
associated CS proteins has not been studied because of the difficulties in obtaining P. 28  CIRCUMSPOROZOITE  PROTEINS  OF  HUMAN MALARIA PARASITES 
vivax and P. falciparum  sporozoites. It should be pointed out, however, that cytoplasmic 
precursors of CS proteins have been found both in P. berghei and P. knowlesi  (11). 1 
The same extracts of metabolically labeled sporozoites were immunoprecipitated 
by the serum of human volunteers vaccinated with x-irradiated sporozoites of P. vivax 
or P. falciparum  and  protected against  infection with the homologous parasite.  It  is 
remarkable that the CS proteins of P. vivax and P. falciparum  were the main polypep- 
tides specifically recognized by these sera  (Figs.  1 and 3).  The CS proteins are also 
among the few polypeptides that can be immunoprecipitated from crude extracts of 
P. berghei and P. knowlesi sporozoites by the serum of vaccinated mice or monkeys (3). 1 
The present and previous findings indicate, therefore, that CS proteins are among the 
most potent immunogens of sporozoites. 
In addition to the CS proteins ofP. vivax and P.falciparurn,  other polypeptides (PfS0, 
Pv78)  are recognized by the serum  of both human  volunteers. These antigens  are 
probably not membrane associated because the sera of the human volunteers do not 
cross-react with membrane antigens of heterologous species as shown by IFA and CSP 
reactions (Table I). 
Of interest is the observation that  the monoclonal anti-CS protein of P.  knowlesi 
(2G3) cross-reacted with the CS protein ofP. falciparum.  The fact that this monoclonal 
neutralized the infectivity of P. knowlesi for monkeys  1 lends additional support to the 
data in the present paper indicating that the CS proteins of P. falciparum  and P. vivax 
can be the target of protective antibodies. Moreover, recent studies using monoclonals 
have also revealed the presence of cross-reactive epitopes in CS proteins of rodent (P. 
berghei, P. yoelii nigeriensis) (N. Yoshida, R. Nussenzweig, and V. Nussenzweig, manu- 
script in preparation) and simian (P. knowlesi, P. cynomolg~)1 malarias. Taken together, 
these observations suggest that CS proteins might belong to a family of related surface 
molecules with shared as well as species-specific structural  features and a  common 
function perhaps essential for the development and penetration of the parasite into 
the target cell. The apparent simplicity and conservation of the antigenic repertoire 
of the CS proteins should  facilitate the immunoprophylaxis of malaria based on a 
sporozoite vaccine. 
Summary 
Monoclonal antibodies were raised against  sporozoites of two species of malaria 
parasites,  Plazmodium falciparum  and  Plazmodium  vivax. The  antibodies  reacted  with 
polypeptides (circumsporozoite proteins) that are uniformly distributed over the entire 
surface of sporozoites, as shown by indirect immunofluorescence and by the circum- 
sporozoite precipitin reaction. The epitopes recognized by the monoclonal antibodies 
were expressed on sporozoites from different geographical isolates of the homologous 
species but  were not  detected on sporozoites of heterologous species nor on  blood 
forms of the parasite. 
The  monoclonal  antibody  to  P. fakiparum  specifically immunoprecipitated  two 
polypeptides of apparent 67,000 mol wt (Pf67) and 58,000 mol wt (Pf58) from extracts 
of [~S]methionine-labeled P. falciparum  sporozoites. Similarly, the anti-P, vivax mono- 
clonal immunoprecipitated two proteins of 51,000 mol wt (Pv51) and 45,000 mol wt 
(Pv45) from extracts of metabolically labeled P. vivax sporozoites. The extracts were 
also reacted with the serum of human volunteers successfully vaccinated with sporo- NARDIN ET AL.  29 
zoites of either P.  vivax  or P. falciparum.  The patterns of immunoprecipitation were 
almost identical to those obtained with the corresponding monoclonal antibodies. 
The circumsporozoite proteins of P. falciparum  and P.  vivax play a  role in immune 
protection. Incubation of the appropriate monoclonal antil6ody with viable sporozoites 
of the homologous species significantly reduced parasite infectivity, as determined by 
sporozoite neutralization assays carried out in splenectomized chimpanzees. 
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